Evaluation of Serum IL-41 Level in Patients With Ankylosing Spondylitis and Psoriatic Arthritis

NCT07648836 | Not Yet Recruiting

• 1 other identifier: SFA AS-Psa
• Study Type: observational
• Target: 90
• Locations: 0 countries
• Sites: N/A

Brief Summary

Psoriatic arthritis (PsA) and ankylosing spondylitis (AS) are chronic inflammatory diseases within the spectrum of spondyloarthritis, characterized by immune-mediated inflammation and progressive functional impairment. Meteorin-like protein (Metrnl) is a novel adipomyokine with potential immunomodulatory and anti-inflammatory properties; however, its role in spondyloarthritis remains incompletely understood. This study aims to evaluate serum Metrnl levels in patients with PsA and AS compared with healthy controls and to investigate their association with disease activity, inflammatory markers, and clinical manifestations. The findings may provide insights into the potential role of Metrnl as a biomarker of disease activity and inflammation in spondyloarthritis.

Conditions

Ankylosing Spondylitis; Psoriasis

Keywords

Ankylosing spondylitis; psoriasis; biomarker

Outcome Measures

Primary Outcomes (1)

• • Serum IL41 differences among AS, PsA, and controls

  1month

Study Arms (3)

psoriatic arthritis patients

Diagnostic Test: IL 41

Ankylosing spondylitis Patients

AS diagnosed according to the modified New York criteria

Diagnostic Test: IL 41

control

apparentely healthy controls

Diagnostic Test: IL 41

Interventions

IL 41 DIAGNOSTIC_TEST

Serum levels of meteorin-like protein (Metrnl) will be measured using a commercially available enzyme-linked immunosorbent assay (ELISA) kit according to the manufacturer's instructions.

Ankylosing spondylitis Patients; control; psoriatic arthritis patients

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

AS diagnosed according to the modified New York criteria, while PsA diagnosed based on the CASPAR criteria,

You may qualify if:

• patients diagnosed with ankylosing spondylitis (AS)and psoriatic arthritis (PsA), in addition to age- and sex-matched healthy controls.
• AS diagnosed according to the modified New York criteria, while PsA was diagnosed based on the CASPAR criteria.

You may not qualify if:

• Patients under the age of 18 years, patients with other autoimmune diseases, diabetes mellitus, chronic kidney or liver disease, active infection, or malignancy were excluded to avoid confounding factors affecting inflammatory markers.

Sponsors & Collaborators

• Assiut University: lead

Related Publications (1)

• Li Z, Gao Z, Sun T, Zhang S, Yang S, Zheng M, Shen H. Meteorin-like/Metrnl, a novel secreted protein implicated in inflammation, immunology, and metabolism: A comprehensive review of preclinical and clinical studies. Front Immunol. 2023 Feb 24;14:1098570. doi: 10.3389/fimmu.2023.1098570. eCollection 2023.

  PMID: 36911663 RESULT

MeSH Terms

Conditions

Spondylitis, Ankylosing; Psoriasis

Condition Hierarchy (Ancestors)

Axial Spondyloarthritis; Spondylarthropathies; Spondylarthritis; Spondylitis; Spinal Diseases; Bone Diseases; Musculoskeletal Diseases; Ankylosis; Joint Diseases; Arthritis; Skin Diseases, Papulosquamous; Skin Diseases; Skin and Connective Tissue Diseases

Central Study Contacts

Sara Farrag lecturer of rheumatology and rehabilitation, lecturer

CONTACT

+01097767735; sara_farrag@aun.edu.eg

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: lecturer of rheumatology and rehabilitation

Study Record Dates

• First Submitted: June 10, 2026
• First Posted: June 15, 2026
• Study Start (Estimated): July 1, 2026
• Primary Completion (Estimated): July 1, 2026
• Study Completion (Estimated): July 30, 2026
• Last Updated: June 15, 2026

Record last verified: 2026-06

Data Sharing

• IPD Sharing: Will not share